๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Interleukin-2 and interferon-alpha2bas a daily alternating schedule in advanced renal cell cancer

โœ Scribed by L. Bergmann; E. Weidmann; H. M. Enzinger; K. Fenchel; D. Jonas; P. S. Mitrou

Publisher
Springer-Verlag
Year
1991
Tongue
English
Weight
377 KB
Volume
9
Category
Article
ISSN
0724-4983

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Immunotherapy of advanced renal cell can
Immunotherapy of advanced renal cell cancer using subcutaneous recombinant interleukin-2 and interferon-ฮฑ
โœ H. Kirchner; W. Riese; E. Allhoff; H. Poliwoda; J. Atzpodien ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Springer-Verlag ๐ŸŒ English โš– 450 KB

The combined administration of subcutaneous recombinant human interleukin-2 (rIL-2) and interferon-a (rIFN-~) was studied in a phase II trial on patients with advanced progressive renal cell cancer. Safety, tolerance and clinical response rate of this outpatient treatment protocol were assessed in 2

5-fluorouracil and interferon-alpha-2a i
5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules
โœ William J. John; John R. Neefe; John S. Macdonald; Jim Cantrell Jr.; Marietta Sm ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 505 KB

Background. Potential synergy between 5-fluorouracil (5-FU) and interferon alpha-2a (IFN-a-Za) has been demonstrated in the treatment of colorectal carcinoma. Continuous low-dose infusion of 5-FU may have superior response rates to bolus 5-FU in these malignancies. This report presents results of tw

A phase I study of recombinant human int
A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma
โœ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN